Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours

N.E. Schoemaker; I. Kuppens; W.W.T. Huinink; P Lefebvre; J.H. Beijnen; S. Assadourian; G.J. Sanderink; J.H.M. Schellens

Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours

N.E. Schoemaker, I. Kuppens, W.W.T. Huinink, P Lefebvre, J.H. Beijnen, S. Assadourian, G.J. Sanderink, J.H.M. Schellens

extern

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	263-270
Number of pages	8
Journal	Cancer Chemotherapy and Pharmacology
Volume	55
Issue number	3
Publication status	Published - 2005

Cite this

@article{97a3208545a040dfacc61c4078c9f7fe,

title = "Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours",

author = "N.E. Schoemaker and I. Kuppens and W.W.T. Huinink and P Lefebvre and J.H. Beijnen and S. Assadourian and G.J. Sanderink and J.H.M. Schellens",

year = "2005",

language = "Undefined/Unknown",

volume = "55",

pages = "263--270",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "1432-0843",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "3",

}

TY - JOUR

T1 - Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours

AU - Schoemaker, N.E.

AU - Kuppens, I.

AU - Huinink, W.W.T.

AU - Lefebvre, P

AU - Beijnen, J.H.

AU - Assadourian, S.

AU - Sanderink, G.J.

AU - Schellens, J.H.M.

PY - 2005

Y1 - 2005

M3 - Article

SN - 1432-0843

VL - 55

SP - 263

EP - 270

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 3

ER -